Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
clinical trial  clinical  company  marketwired sep  marketwired september  marketwired  medical  sep  september  today  trial 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Tue, 19 Sep 2017 20:59:09 EDT

Copyright: Copyright: (C) Marketwired
 



Acquisition and Disposition of Securities of Hemostemix Inc.

Tue, 19 Sep 2017 20:28:52 EDT

CALGARY, ALBERTA--(Marketwired - Sept. 19, 2017) - Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired 88,000,000 units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE:HEM), with each Unit consisting of one common share (a "Share") of the Issuer and one-half Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder to acquire one additional Share for CDN$0.20 for a period of 2 years from the issuance of the Warrants, with an accelerated exercise provision attached to each Warrant commencing on the day following (x) the issuance of the Warrants and (y) the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Issuer exceeds CDN $1.00, then the Issuer may elect to accelerate the expiry date by providing the Warrant holders, 30 days' notice by way of a press release of the accelerated expiry date.




Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Tue, 19 Sep 2017 10:30:00 EDT

HICKSVILLE, NY--(Marketwired - Sep 19, 2017) - Canbiola, Inc. (OTC PINK: CANB) announced today that the company has added Dr. Fratellone to its Medical Advisory Board and engaged Dr. Fratellone as a distributor for Canbiola products. Dr. Fratellone is an attending physician at St. Luke's Hospital, Roosevelt Hospital, and Beth Israel Hospital, and current professor at University of Bridgeport College of Naturopathic Medicine. In addition, he bridges East Meets West at the Center of Excellence in Bridgeport CT with author Dr. Peter D'Adamo of Eat Right for Your Blood Type. Dr. Fratellone has appeared on multiple shows, and is considered an expert in his field as well a visionary. Dr. Fratellone stated, "As one of the few MDs in the US who is also a registered herbalist, I believe in traditional and time honored treatments, but also to look outside of the box; to that end CBD is certainly part of the future in my opinion with clear benefits to patients. I look forwarded to working with Canbiola, as well as educating the public on the vast benefits of CBD through blogs and speaking engagements."




FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature

Tue, 19 Sep 2017 10:02:29 EDT

IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs




Avadim Technologies Inc. Announces Partnership With Cardinal Health, Inc.

Tue, 19 Sep 2017 09:15:00 EDT

Cardinal Health, a Global, Integrated Healthcare Services and Products Company Ranked #15 of Fortune 500 Companies, Will Now Supply Theraworx(R) Technology to its Acute Care and Long-Term Care Customers




Pivot Pharma Looks to Improve Cannabinoid Bioavailability with Topical BiPhasix(TM) Delivery System -- CFN Media

Tue, 19 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) and its recent acquisition of the BiPhasixT Transdermal Drug Delivery technology for the delivery of cannabinoids.




Medovex Corporation Launches DenerveX System in Spain with Distributor Prim SA

Tue, 19 Sep 2017 08:30:00 EDT

Training and First Order Scheduled for Week of September 19th




Rennova Health Announces Big South Fork Medical Center Provided Services to Over 1,000 Patients in First Month of Operation

Tue, 19 Sep 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - September 19, 2017) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces that Big South Fork Medical Center's Emergency Room has received 1,005 visits in its first month of operation and admitted 45 patients for overnight stays.




Cannabis Science "Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids" Full Publication Released Today In Frontiers In Oncology

Tue, 19 Sep 2017 08:18:05 EDT

IRVINE, CA--(Marketwired - Sep 19, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the full publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal, Frontiers in Oncology, released today.




Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

Tue, 19 Sep 2017 08:00:00 EDT

Novel Injectable Formulation for Potential Twice Per Year Treatment




Pharmacology to Payer: One Quantitative Drug Development Framework to Rule Them All

Tue, 19 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 19, 2017) - This webinar will discuss how "pharmacology to payer" (P2P) can be used as a quantitative framework that bridges the disciplines of pharmacology, epidemiology, and health economics to support meaningful dialogue between industry, regulators, and payers.




Biologics in Dermatology: Considerations for Patients and Clinical Trials, New Webinar Hosted by Xtalks

Tue, 19 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 19, 2017) - In an upcoming presentation experts Darcee Duke Strube, Senior Vice President of Novella Clinical's Dermatology Division and Dr. James J Milbauer, Dermatologist, Medical Monitor and Advisor will discuss the evolution of biologics within the dermatology landscape, with an emphasis on clinical trial considerations for sponsors developing biologic agents.




Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases

Tue, 19 Sep 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - Sept. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment of liver diseases.




Industry Leader, Darren Cherry, Leads Advantis Corp. Into the Future

Tue, 19 Sep 2017 01:53:03 EDT

NEWPORT BEACH, CA--(Marketwired - Sep 19, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it has agreed with leading wholesale, marketing, and logistics expert, Darren Cherry, to take the helm as its new CEO.




FRDJ et la Financière Sun Life font équipe pour amasser des fonds destinés à la recherche sur le diabète

Mon, 18 Sep 2017 16:33:42 EDT

La Révolution FRDJ Roulons met les Canadiens au défi de se dépasser et de récolter de l'argent pour vaincre le diabète de type 1




JDRF and Sun Life Financial team up to raise funds for diabetes research

Mon, 18 Sep 2017 16:33:07 EDT

The JDRF Revolution Ride challenges Canadians to go further and raise funds to defeat type 1 diabetes




Medigus Announces Second Quarter 2017 Financial Results

Mon, 18 Sep 2017 16:05:00 EDT

OMER, ISRAEL--(Marketwired - Sep 18, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and direct visualization technology, today announced financial results for the second quarter ended June 30, 2017.




Pressure BioSciences' Next-Generation Barocycler 2320EXTREME Named a Finalist in the Prestigious 2017 R&D 100 Awards

Mon, 18 Sep 2017 09:46:37 EDT

Considered Among the Most Prestigious Recognitions of Invention and Innovation Worldwide, the R&D 100 Awards Identify the Top 100 Revolutionary Technologies of the Past Year




GeoVax Provides Update on its Zika Vaccine Development

Mon, 18 Sep 2017 09:00:00 EDT

Presentation Made During 11th Vaccine Congress in San Diego




MediXall Group, Inc. Creates Multiple Revenue Streams in September 2017

Mon, 18 Sep 2017 08:00:00 EDT

FT. LAUDERDALE, FL--(Marketwired - Sep 18, 2017) - MediXall Group, Inc. (OTCQB: MDXL) announced today that three additional revenue streams are in place and operational, creating additional value in the company. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. Prior to the planned October launch of the MediXaid Healthcare Platform, a subsidiary of MediXall Group with over 3,500 practitioners and diagnostic centers participating, to date, the company has signed agreements with strategic partners, SafeRide and PWeR®, who offer strong solutions to help network practitioners grow their businesses.




Tetra Bio-Pharma getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks

Mon, 18 Sep 2017 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - Sept. 18, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. The corporation worked with physicians of Sante Cannabis to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients. In addition, as part of the clinical trial, Tetra will collect the pharmacoeconomics evidence required from provincial insurers in order to support the reimbursement of the first cannabis prescription drug.




Les données à long terme sur l'efficacité et l'innocuité de l'ibalizumab présentées à IDWeek 2017 à San Diego

Mon, 18 Sep 2017 07:43:55 EDT

MONTRÉAL, QUÉBEC--(Marketwired - 18 sept. 2017) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) a annoncé aujourd'hui qu'un résumé d'étude intitulé "48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1" fera l'objet d'une présentation orale lors de la conférence IDWeek qui aura lieu à San Diego, en Californie, du 4 au 8 octobre 2017. Dr. Brinda Emu, professeur adjoint de médecine, maladies infectieuses, Faculté de médecine de l'université Yale à New Haven au Connecticut, présentera les données à long terme détaillées de l'efficacité et l'innocuité de l'ibalizumab, un médicament présentement sous étude. La présentation aura lieu en après-midi durant la séance du 6 octobre 2017 intitulée Modern ART (NDLT : Traitements anti-rétroviraux modernes).




Ibalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San Diego

Mon, 18 Sep 2017 07:43:36 EDT

MONTREAL, QUEBEC--(Marketwired - Sept. 18, 2017) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the abstract entitled "48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1" will be featured in an oral presentation at the IDWeek Conference to be held in San Diego, CA, from October 4 to 8, 2017. Dr. Brinda Emu, Assistant Professor of Medicine, Infectious Diseases, Yale School of Medicine, New Haven, CT will be presenting detailed data related to the long-term efficacy and safety of ibalizumab, an investigational drug. The presentation will be held during the afternoon session on October 6, 2017, entitled Modern ART.




What Does it Take to Successfully Execute Large, Global, Phase III Programs?

Mon, 18 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 18, 2017) - In a complimentary webinar taking place on Tuesday, October 3, 2017 at 10am EDT (3pm BST/UK), INC Research/inVentiv Health leaders Clifford McIntosh, Vice President of Strategic Alliance Management and Alexandria Wise-Rankovic, Ph.D., Senior Vice President of Clinical Development, CNS reveal a proven method to thrive in large, global, Phase III Programs.




Why Track and Trace Isn't Just Tracking and Tracing: Best Practices for Implementing a Solution That Works

Mon, 18 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 18, 2017) - In an upcoming webinar on Wednesday, October 4, 2017, industry expert Joe Lipari, Director of Cloud Products at Systech International will discuss a holistic approach towards designing and achieving a successful Track and Trace solution.




REMINDER - Optymyze to Highlight Best Practices for Leveraging Sales Data at PharmaForce 2017

Mon, 18 Sep 2017 07:00:00 EDT

CHESTER, PA--(Marketwired - Sep 18, 2017) -




Chiesi Salutes Nurses on Neonatal Nurses Day 2017

Fri, 15 Sep 2017 09:00:00 EDT

Neonatal nurses celebrated by colleagues and Chiesi for their commitment to babies




Lugano 2014 Criteria for Assessing FDG-PET/CT in Lymphoma: An Operational Approach for Clinical Trials

Fri, 15 Sep 2017 08:15:21 EDT

The goal of this webinar hosted by Xtalks is to discuss the evolution of the role of imaging in the assessment of lymphomatous disease




Development and Manufacture of HPAPI Drug Products through the Clinical Phases from molecule to market, New Webinar Hosted by Xtalks

Fri, 15 Sep 2017 08:12:31 EDT

TORONTO, ON--(Marketwired - September 15, 2017) - This webinar will share how highly potent APIs can be developed and manufactured into suitable drug dosage forms including; solid oral, non-sterile oral liquids and semi-solid creams and ointments whilst adhering to the highest quality standards. Attendees will learn about the complexities at each stage of the development lifecycle, from the earliest phase of First in Man (FiM) studies involving drug in capsule, moving through ongoing clinical development and process optimization of often complex formulations ultimately resulting in commercialization and global supply.




Dewmar International BMC, Inc. (DEWM) Announces Synergy with Duck Commander CEO Willie Robertson for Donation of Medical Supplies and More to Hurricane Harvey Shelters

Fri, 15 Sep 2017 07:36:40 EDT

HOUSTON, TX--(Marketwired - Sep 15, 2017) - Dewmar International BMC, Inc. (OTC PINK: DEWM), a diversified brand management and operating company, announces that along with its operating partner, Willie Robertson, Dewmar and Mr. Robertson provided valuable donations of medical equipment, devices, clothing, outdoor wear and more to assist Hurricane Harvey victims and first-responders in the Greater Houston area.




Most Surveyed Pharma Companies Choose to Fund Dedicated Continuing Medical Education Programs

Thu, 14 Sep 2017 18:51:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - September 14, 2017) - About 77% of surveyed global medical affairs teams consider dedicated CME providers as their first choice when funding continuing medical education (CME) programs, according to a recent study by industry intelligence provider, Cutting Edge Information.




CORRECTION - BioVie Inc.

Thu, 14 Sep 2017 15:37:58 EDT

BEVERLY, MA --(Marketwired - September 14, 2017) - In the news release, "First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites," issued earlier today by BioVie Inc. (OTCQB: BIVI), we are advised by the company that the title of the release should read "First Patient Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites". Complete corrected text follows.




Tauriga Sciences, Inc. Completes Reformulation of its Cupuacu Butter Based Lip Balm Product; First Tranche of Marketable Inventory Expected by End of Month

Thu, 14 Sep 2017 12:24:48 EDT

NEW YORK, NY--(Marketwired - Sep 14, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that it has completed the reformulation of its Cupuacu Butter lip balm product (Branded as: HERMAN). In addition, the company expects the first (initial) tranche of marketable product to be available by the end of September 2017. The Company has worked cooperatively with its licensor, Ice + Jam LLC ("Ice + Jam") as well as cosmetics industry R & D firm, Ariel Laboratories ("Ariel Labs") to develop this substantially improved product; in preparation for the anticipated retail launch -- Scheduled for mid-late Autumn 2017.




Tauriga Sciences, Inc. Secures $210,000 in Long Term Financing from Existing Institutional Investor

Thu, 14 Sep 2017 10:26:28 EDT

NEW YORK, NY--(Marketwired - Sep 14, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that it has secured $210,000 in long term financing from an existing institutional investor. Under terms of the financing agreement, the Company received $30,000 USD upon signing with the balance of $180,000 being deferred until after March 11, 2018. The financing structure consists of one $30,000 convertible debenture with 6 distinct $30,000 "Back End" convertible debentures which are eligible to be funded at any time between March 11, 2018 -- September 11, 2018. A detailed disclosure of the material terms of this financing agreement will be provided to shareholders on Form 8-K to be filed by the Company within the next few business days.




CureDots(TM) Look to Redefine How Animal Clinical Trials Are Conducted -- CFN Media

Thu, 14 Sep 2017 09:30:00 EDT

SEATTLE, WA--(Marketwired - Sep 14, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining CURE Pharmaceutical's (OTCQB: CURR) recently developed CureDotsT, a more humane and effective technique for administering drugs to animals.




Medovex Corporation Initiates Forward Integration-Direct Sales Operations Strategy on Heels of Initial Strong Sales Opportunity in Key German Market

Thu, 14 Sep 2017 08:30:00 EDT

Gains a Strategic Edge Bringing Physicians, Hospitals and Patients Closer




Cannabis Science Announces Publication of Initial Research Results Using Nanoparticle Drones to Target Lung Cancer With Radiosensitizers and Cannabinoids in the Renowned Journal Frontiers in Oncology

Thu, 14 Sep 2017 08:05:22 EDT

IRVINE, CA--(Marketwired - Sep 14, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal Frontiers in Oncology.




Velano Vascular and Partners to Address Medical Device Innovation and Vascular Access Advances in September

Thu, 14 Sep 2017 08:05:00 EDT

SAN FRANCISCO, CA--(Marketwired - Sep 14, 2017) - Vascular access technology innovator Velano Vascular today announced that company leadership and several partners will present at a number of premier healthcare conferences in September.




Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer

Thu, 14 Sep 2017 08:05:00 EDT

PRINCETON, NJ--(Marketwired - September 14, 2017) -




Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance, New Webinar Hosted by Xtalks

Thu, 14 Sep 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - September 14, 2017) - The live session taking place on Tuesday, September 26, 2017 at 11am EDT (4pm BST/UK) will present case studies of how trial sponsors and CROs are:




Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Thu, 14 Sep 2017 08:00:00 EDT

Presentation with live audio webcast on Monday, September 25th at 8:35 AM EDT




First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites

Thu, 14 Sep 2017 08:00:00 EDT

BEVERLY, MA--(Marketwired - September 14, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today confirmed enrollment of the first patient in the Company's mid-stage (Phase 2a) clinical trial of BIV201 for the treatment of patients with refractory ascites due to liver cirrhosis. The initial trial is being led by Jasmohan Bajaj, MD, MS, study site principal investigator (PI) at the McGuire Research Institute in Richmond, VA.




HempAmericana, Inc. (HMPQ) Purchases 200L SuperCritical CO2 Extractor To Begin Mass Production

Thu, 14 Sep 2017 08:00:00 EDT

On The Heels of The Launch of New Operations in Maine, HempAmericana Launches Multi-Million Dollar Initiative




Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned, Upcoming Webinar Hosted by Xtalks

Thu, 14 Sep 2017 07:30:00 EDT

TORONTO, ON --(Marketwired - September 14, 2017) - In this complimentary webinar taking place on Monday September 25, 2017,11am EDT (4pm BST/UK), a team of experts from Clinipace Worldwide will examine high-profile Phase 3 trial failures and discuss lessons learned.




Fresenius Medical Care unveils Malaysia's first Peritoneal Dialysis products Manufacturing Plant

Thu, 14 Sep 2017 01:22:31 EDT

SEREMBAN, MALAYSIA--(Marketwired - Sep 14, 2017) -  Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, expanded its regional manufacturing plant in Bandar Enstek, Malaysia. Dato' Seri Dr. Chen Chaw Min, Secretary General of the Malaysian Ministry of Health graced the opening ceremony.




Sirona Biochem Announces Resignation of Board Director

Wed, 13 Sep 2017 16:16:34 EDT

VANCOUVER, BC--(Marketwired - September 13, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Dr. Martin Gleave from the board of directors. Dr. Gleave is involved in a new venture that could result in a potential conflict. Accordingly both Dr. Gleave and the Company felt a resignation was most appropriate.




Angle PLC: Holding(s) in Company

Wed, 13 Sep 2017 13:47:04 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Sep 13, 2017) - (AIM: AGL) (OTCQX: ANPCY)




Survey Shows Rheumatoid Arthritis Patients Struggle to Explain Unseen Symptoms

Wed, 13 Sep 2017 13:35:00 EDT

More than Half of Respondents Have Changed Doctors over Their Healthcare Journey




UC Irvine Division of Continuing Education Offers Event to Educate Certificate Program Earners on the Opportunity to Apply Credits Towards a Master's Degree

Wed, 13 Sep 2017 11:40:00 EDT

Free Panel Discussion Held on Oct. 5 at UC Irvine Campus; Must Register to Attend




Protext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes

Wed, 13 Sep 2017 10:16:58 EDT

Company's Near Term Goal to Sell Phytofare® as a Primary Therapy Protocol




CFN Media Takes a Video Look into Future Farm's Cutting-Edge Facility

Wed, 13 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 13, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, recently published an exclusive video that takes a look into Future Farm Technologies Inc.'s (CSE: FFT) (CNSX: FFT) (FFT.CN) (OTCQB: FFRMF) cutting-edge facility shortly before it harvested its first cannabis crop in California.




NetworkNewsWire Announces Publication Discussing Innovative Drug Developments in the Global Marijuana Market

Wed, 13 Sep 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Sep 13, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.




Microbix Announces First Shipment of Bioreactor Antigen

Wed, 13 Sep 2017 08:30:00 EDT

Customer Validation of New Manufacturing Process Completed




Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai

Wed, 13 Sep 2017 08:24:11 EDT

SAN FRANCISCO, CA--(Marketwired - September 13, 2017) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that its CEO, Dr Gergely Tóth, will present at the 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai, China on September 14, 2017 at 4:15pm, 2nd floor Main Building, Intercontinental Shanghai Rujin. Dr Tóth will present a company update with a summary of the latest research findings from the company's CB101 and CB201 programs targeting the DJ-1 protein for the treatment of Alzheimer's and Parkinson's, and will report on the potential application of CB101 candidates in protecting from methylglyoxal activity, as found in type 2 diabetes.




Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma

Wed, 13 Sep 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - September 13, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has engaged contract research organization ("CRO") Bioscience SA ("Bioscience") to prepare for a proof-of-concept clinical trial in Poland to study its drug candidate WP1220 for the treatment of cutaneous T-cell lymphoma ("CTCL").




Innovation through Integration - Providing Next Generation Biomedical Devices and Interconnects

Wed, 13 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 13, 2017) - In a complementary Xtalks webinar scheduled for Friday, September 22, 2017 at 2pm EDT, industry expert Steve Groothuis, Chief Technology Officer at Samtec Microelectronics will provide insight into new packaging concepts, interconnects.




mCig, Inc. Raising up to $3 Million in Financing for Expansion of Operations

Wed, 13 Sep 2017 07:00:00 EDT

LAS VEGAS, NV--(Marketwired - Sep 13, 2017) - mCig Inc., (OTCQB: MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, is pleased to announce that it is concluding efforts to raise up to $3 million under a private placement to qualified accredited investors for the expansion of its operations.




Optymyze to Highlight Best Practices for Leveraging Sales Data at PharmaForce 2017

Wed, 13 Sep 2017 07:00:00 EDT

CHESTER, PA--(Marketwired - Sep 13, 2017) -




Equate Health Joins UC Davis and Healbe for Nutrition and Health Innovation Research Collaboration

Wed, 13 Sep 2017 03:01:00 EDT

Equate Health Supplies its AI and Machine Learning Tools to Help Create Technology-Driven and Knowledge-Based Health Platform to Combat Metabolic Imbalance and Chronic Disease




Angle PLC: Exclusive Worldwide Option Over Megakaryocyte Intellectual Property

Wed, 13 Sep 2017 02:00:00 EDT

GUILDFORD, SURREY--(Marketwired - Sep 13, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)